FDA and clinical trial data monitoring committees

Data Monitoring in Clinical Trials: A Case Studies Approach

Volumn , Issue , 2006, Pages 39-49

  Ellenberg, Susan S ^a   Siegel, Jay P ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889828152     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-30107-0_3     Document Type: Chapter

References (19)

1. U. S. Food and Drug Administration. 1988. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, MD: FDA. http://www.fda.gov/cder/guidance/statnda.pdf.
2. Ellenberg SS, Geller N, Simon R, Yusuf S (eds.). 1993. Proceedings of "Practical Issues in Data Monitoring of Clinical Trials", Bethesda, Maryland, USA, 27-28 January 1992. Stat Med 12:415-616.
3. O'Neill RT. 1993. Some FDA perspectives on data monitoring in clinical trials in drug development. Stat Med 12:601-608.
4. O'Neill RT. 1993. A regulatory perspective on data monitoring and interim analysis. In Buncher CR, Tsay JY (eds.): Statistics in the Pharmaceutical Industry. Marcel Dekker, New York.
5. Title 21, US Code of Federal Regulations. Part 50.24
6. Ellenberg SS. 1997. Informed consent: Protection or obstacle? Some emerging issues. Control Clin Trials 18:628-636.
7. US Food and Drug Administration. 1998. International Conference on Harmonisation: Guidance on Statistical Principles for Clinical Trials. http://www.fda.gov/cber/gdlns/ichclinical.pdf.
8. ICH E9 Expert Working Group 1999. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials. Stat Med 18:1905-1942.
9. US Food and Drug Administration. 2001. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. FDA, Rockville, MD. http://www.fda.gov/cber/gdlns/clindatmon.htm.
10. Title 21, US Code of Federal Regulations, Parts 314.500-314.560. http://straylight.law. cornell.edu/cfr/cfr.php?title=21&type=part&value= 314
11. Murray JM, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. 1999. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 13:797-804.
12. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429-436.
13. Siegel JP. 2002. Biotechnology and clinical trials. J Infect Dis 185:S52-S57.
14. Derkx B, Wittes J, McCloskey R. 1999. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 28:770-777.
15. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. 1994. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebocontrolled trial. CHESS Trial Study Group. Ann Intern Med 121:1-5.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1588.
17. PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504.
18. Goodkin DE. 1998. Interferon β therapy for multiple sclerosis. Lancet 352:1486-1500.
19. U. S. Food and Drug Administration. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. http://www.fda.gov/cder/guidance/1397fnl.pdf